Latest From Genovis AB
Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.
The Swedish group has sold its stake in Genovis, raising about $9.6m that will help advance lead candidate imlifidase.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
- Large Molecule
- In Vitro Diagnostics
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
- Diagnostic Imaging Equipment & Supplies
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Genovis AB
- Senior Management
- Fredrik Olsson, CEO
- Contact Info
Phone: 046 101230
P.O. Box 790 Lund, SE-22363
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.